List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion Fludarabine Accord Healthcare 25 mg/ml Concentraat voor oplossing voor injectie of infusie Fludarabine Accord 25 mg/ml, süste- või infusioonilahuse kontsentraat Fludarabin Accord 25 mg/ml koncentrátum oldatos injekcióhoz vagy infúzióhoz Fludarabin Accord 25 mg/ml koncentrátum oldatos injekcióhoz vagy infúzióhoz Fludarabin Accord 25 mg/ml koncentrátum oldatos injekcióhoz vagy infúzióhoz Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion UK/H/5564/001 BE ACCORD HEALTHCARE UK/H/5564/001 BE ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/001 OGYI-T-22726/01 ACCORD HEALTHCARE UK/H/5564/001 OGYI-T-22726/02 ACCORD HEALTHCARE UK/H/5564/001 OGYI-T-22726/03 ACCORD HEALTHCARE UK/H/5564/001 PA 1390/096/001 ACCORD HEALTHCARE BE BE EE HU HU HU IE EMA/223740/2018 Page 2/18

3 FludarabineAccord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui FludarabineAccord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui FludarabineAccord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui Fludarabine Accord 25 mg/ml koncentrats injekciju vai infuziju škiduma pagatavošanai Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabinefosfaat Accord 25 mg/ml, concentraat voor oplossing voor injectie of infusie Fludarabine Accord 25 mg/ml Koncentrat till injektions- /infusionsvätska, lösning UK/H/5564/001 LT/1/14/3627/001 ACCORD HEALTHCARE UK/H/5564/001 LT/1/14/3627/002 ACCORD HEALTHCARE UK/H/5564/001 LT/1/14/3627/003 ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/001 MA 054/08401 ACCORD HEALTHCARE UK/H/5564/001 RVG ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE LT LT LT LV MT NL SE EMA/223740/2018 Page 3/18

4 Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabin Accord 25 mg/ml Konzentrat zur Herstellung einer Injektions oder Infusionslösung Fludarabin Accord 25 mg/ml Konzentrat zur Herstellung einer Injektions- /Infusionslösung Fludarabina Accord 25mg/ml concentrado para solução injetável ou para perfusão Fludarabina Accord 25mg/ml concentrado para solução injetável ou para perfusão Fludarabina Accord 25mg/ml concentrado para solução injetável ou para perfusão UK/H/5564/001 PL 20075/0379 ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK AT DE PT PT PT EMA/223740/2018 Page 4/18

5 Fludarabina Accord 25 mg/ml concentrado para solución inyectable y para perfusión. Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione Fludarabine Accord 25 mg/ml koncentrát pro injekční/infuzní roztok Fludarabine Accord 25 mg/ml πυκνό διάλυμα για παρασκευή διαλύματος προς ένεση ή έγχυση Fludarabin Accord 25 mg/ml koncentrat za otopinu za injekciju ili infuziju UK/H/5564/ ACCORD HEALTHCARE S.L.U. ES UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/001 44/476/15-C ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/001 HR-H ACCORD HEALTHCARE IT IT IT CZ CY HR EMA/223740/2018 Page 5/18

6 Fludarabine Accord, 25 mg/ml, koncentrat do sporządzania roztworu do wstrzykiwań lub infuzji Fludarabine Accord 25 mg/ml injektio- /infuusiokonsentraatti, liuosta varten Флударабин Акорд 25 mg/ml концентрат за инжекционен или инфузионен разтвор Fludarabinmedac 25 mg/ml Konzentrat zur Herstellung einer Injektionslösung oder Infusionslösung Fludarabine Teva 25 mg/ml, concentraat voor oplossing voor intraveneuze injectie/infusie Fludarabinphosphat OMNICARE 25 mg/ml Konzentrat zur Herstellung einer Injektionslösung oder Infusionslösung UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE UK/H/5564/ ACCORD HEALTHCARE NL/H/0805/ PHARMACHEMIE B.V DE NL-H RVG TEVA NEDERLAND B.V. NL not available OMNICARE PHARMA GMBH DE PL FI BG EMA/223740/2018 Page 6/18

7 Fludarabin Teva 25 mg/ml koncentrat za raztopino za injiciranje ali infundiranje Fludarabine Teva, 25 mg/ml, koncentrat do sporządzania roztworu do wstrzykiwań lub infuzji Fludarabina Teva 25mg/ml concentrato per soluzione iniettabile o per infusione Fludarabinphosphat Phar machemie, koncentrat til injektions- og infusionsvæske, opløsning Fludarabine-Teva 25 mg/ml, koncentrát pro injekční/infuzní roztok Fludarabina Teva 25 mg/ml, concentrado para solución inyectable y para perfusión EFG NL/H/0715/001 H/07/00630/001 TEVA PHARMA B.V. SI NL/H/0715/ TEVA PHARMACEUTICALS POLSKA SP. Z O.O. NL/H/0715/ TEVA ITALIA S.R.L. IT NL/H/0715/ PHARMACHEMIE B.V DK NL/H/0715/001 44/333/07-C TEVA PHARMACEUTICALS CR, S.R.O. NL/H/0715/ TEVA PHARMA S.L.U ES PL CZ EMA/223740/2018 Page 7/18

8 Fludarabinphosphat- GRY 25 mg/ml Konzentrat zur Herstellung einer Injektionslösung oder Infusionslösung FLUDARABINE TEVA 25 mg/ml, solution à diluer pour injectable ou perfusion Fludarabinefosfaat - PCH 25 mg/ml, concentraat voor oplossing voor infusie of injectie Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie Fludarabine Phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion Fludara 10 mg plėvele dengtos tabletės NL/H/0715/ TEVA GMBH DE NL/H/0715/001 NL32376 TEVA SANTÉ FR NL/H/0715/001 RVG PHARMACHEMIE B.V NL NL/H/0715/001 BE TEVA PHARMA BELGIUM N.V./S.A NL/H/0715/001 PL 00289/0938 TEVA UK UK NL/H/0715/ TEVA PHARMA BELGIUM N.V./S.A not available LT/1/96/2819/002 GENZYME EUROPE B.V. LT BE LU EMA/223740/2018 Page 8/18

9 FLUDARA 10 mg, comprimé pelliculé Fludara oral 10 mg filmcoated tablets Fludara oral 10 mg filmcoated tablets FLUDARA 10 mg, comprimé pelliculé FLUDARA 10 mg, comprimé pelliculé Fludara 50 mg poudre pour solution injectable ou poudre pour solution pour perfusion Fludara 50 mg poeder voor oplossing voor injectie of infusie Fludara 50 mg por oldatos injekcióhoz vagy oldatos infúzióhoz Fludara 50 mg polvere per soluzione iniettabile o per infusion Fludara 50 mg powder for solution for injection/infusion UK/H/0055/ GENZYME EUROPE B.V. LU UK/H/0055/002 PL 12375/0040 GENZYME EUROPE B.V. UK UK/H/0055/002 PA 611/4/2 GENZYME EUROPE B.V. IE UK/H/0055/ GENZYME EUROPE B.V. FR UK/H/0055/ GENZYME EUROPE B.V. FR UK/H/0055/001 BE GENZYME EUROPE B.V. BE UK/H/0055/001 BE GENZYME EUROPE B.V. BE not available OGYI-T 8272/03 GENZYME EUROPE B.V. HU UK/H/0055/ GENZYME EUROPE B.V. IT not available MA596/00301 GENZYME EUROPE B.V. MT EMA/223740/2018 Page 9/18

10 Fludara, poeder voor oplossing voor injectie of infusie 50 mg/flacon Fludara 50 mg pó para solução injectável ou para perfusão Fludara 50 mg prašek za raztopino za injiciranje ali infundiranje Beneflur 50 mg polvo para solución inyectable y para perfusion Fludara 50 mg κόνις για ενέσιμο διάλυμα ή για διάλυμα προς έγχυση Fludara 50 mg κόνις για ενέσιμο διάλυμα ή για διάλυμα προς έγχυση Флудара орал 10 mg филмирани таблетки Fludara 10 mg επικαλυμμένα με λεπτό υμένιο δισκία Fludara 10 mg, potahované tablety Fludara, filmovertrukne tabletter UK/H/0055/001 RVG GENZYME EUROPE B.V. NL UK/H/0055/ GENZYME EUROPE B.V. PT not available H/97/00628/001 GENZYME EUROPE B.V. SI UK/H/0055/ GENZYME EUROPE B.V. ES not available GENZYME EUROPE B.V. CY UK/H/0055/ / GENZYME EUROPE B.V. GR not available ; II-1214/ GENZYME EUROPE B.V. BG not available GENZYME EUROPE B.V. CY not available 44/181/01-C GENZYME EUROPE B.V. CZ UK/H/0055/ GENZYME EUROPE B.V. DK EMA/223740/2018 Page 10/18

11 Fludara 10 mg tabletti, kalvopäällysteinen Fludara 10 mg επικαλυμμένα με λεπτό υμένιο δισκία Fludara 10 mg filmtabletta Fludara 10 mg filmtabletta Fludara 10 mg filmuhúðaðar töflur Fludara 10 mg compresse rivestite con film Fludara 10 mg compresse rivestite con film Fludara 10 mg apvalkotās tabletes Fludara 10 mg plėvele dengtos tabletės FLUDARA 10 mg, comprimé pelliculé Fludara oral 10 mg filmcoated tablets Fludara oraal 10 mg, filmomhulde tabletten Fludara 10 mg tablett, filmdrasjert UK/H/0055/ GENZYME EUROPE B.V. FI UK/H/0055/ / GENZYME EUROPE B.V. GR not available OGYI-T-8272/01 GENZYME EUROPE B.V. HU not available OGYI-T-8272/02 GENZYME EUROPE B.V. HU UK/H/0055/002 IS/1/01/036/01 GENZYME EUROPE B.V. IS UK/H/0055/ GENZYME EUROPE B.V. IT UK/H/0055/ GENZYME EUROPE B.V. IT not available GENZYME EUROPE B.V. LV not available LT/1/96/2819/001 GENZYME EUROPE B.V. LT UK/H/0055/ GENZYME EUROPE B.V. LU not available MA596/00302 GENZYME EUROPE B.V. MT UK/H/0055/002 RVG GENZYME EUROPE B.V. NL UK/H/0055/ GENZYME EUROPE B.V. NO EMA/223740/2018 Page 11/18

12 Fludara Oral, 10 mg, tabletki powlekane Fludara oral 10 mg, comprimate filmate Fludara oral 10 mg, comprimate filmate Fludara oral 10 mg filmom obalené tablety Fludara 10 mg filmsko obložene tablete Beneflur10 mg comprimidos recubiertos con película Fludara 10 mg filmdragerad tablett Fludara 50 mg powder for solution for injection/infusion Fludara 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslosung FLUDARA 50 mg, poudre pour solution injectable ou perfusion Fludara 50 mg powder for solution for injection/infusion not available GENZYME EUROPE B.V. PL not available 1229/2008/01 GENZYME EUROPE B.V. RO not available 1229/2008/02 GENZYME EUROPE B.V. RO not available 44/0001/03-S GENZYME EUROPE B.V. SK not available H/97/00628/002 GENZYME EUROPE B.V. SI UK/H/0055/ GENZYME EUROPE B.V. ES UK/H/0055/ GENZYME EUROPE B.V. SE UK/H/0055/001 PA 611/4/1 GENZYME EUROPE B.V. IE UK/H/0055/ GENZYME EUROPE B.V. DE UK/H/0055/ GENZYME EUROPE B.V. FR UK/H/0055/001 PL 12375/0039 GENZYME EUROPE B.V. UK EMA/223740/2018 Page 12/18

13 Fludara 10 mg επικαλυμμένα με λεπτό υμένιο δισκία Флудара орал 10 mg филмирани таблетки Fludara oral 10 mg filmom obalené tablety Fludara 10 mg apvalkotās tabletes Fludara oral 10 mg filmcoated tablets Fludara Oral, 10 mg, tabletki powlekane Fludara 10 mg, potahované tablety Fludara oral 10 mg filmcoated tablets Fludara 10 mg επικαλυμμένα με λεπτό υμένιο δισκία Fludara 10 mg tablett, filmdrasjert Fludara oral 10 mg filmcoated tablets Fludara, filmovertrukne tabletter Fludara 10 mg filmuhúðaðar töflur not available GENZYME EUROPE B.V. CY not available ; II-1214/ GENZYME EUROPE B.V. BG not available 44/0001/03-S GENZYME EUROPE B.V. SK not available GENZYME EUROPE B.V. LV not available MA596/00302 GENZYME EUROPE B.V. MT not available GENZYME EUROPE B.V. PL not available 44/181/01-C GENZYME EUROPE B.V. CZ UK/H/0055/002 PL 12375/0040 GENZYME EUROPE B.V. UK UK/H/0055/ / GENZYME EUROPE B.V. GR UK/H/0055/ GENZYME EUROPE B.V. NO UK/H/0055/002 PA 611/4/2 GENZYME EUROPE B.V. IE UK/H/0055/ GENZYME EUROPE B.V. DK UK/H/0055/002 IS/1/01/036/01 GENZYME EUROPE B.V. IS EMA/223740/2018 Page 13/18

14 Fludara 10 mg tabletti, kalvopäällysteinen Beneflur10 mg comprimidos recubiertos con película Fludara oraal 10 mg, filmomhulde tabletten Fludarabin Actavis 25 mg/ml koncentrat till injektions- /infusionsvätska, lösning Fludarabin Actavis 25mg/ml concentrate for solution for injection or infusion Fludarabin Actavis 25mg/ml concentrate for solution for injection or infusion Fludarabine Actavis, 25 mg/ml, süste- või infusioonilahuse kontsentraat FLUDARABINE ACTAVIS 25 MG/ML KONCENTRĀTS INJEKCIJU VAI INFŪZIJU ŠĶĪDUMA PAGATAVOŠANAI UK/H/0055/ GENZYME EUROPE B.V. FI UK/H/0055/ GENZYME EUROPE B.V. ES UK/H/0055/002 RVG GENZYME EUROPE B.V. NL UK/H/5290/ ACTAVIS GROUP PTC EHF. SE UK/H/5290/ ACTAVIS GROUP PTC EHF. NO UK/H/5290/001 PA 1380/134/1 ACTAVIS GROUP PTC EHF. IE UK/H/5290/ ACTAVIS GROUP PTC EHF. EE UK/H/5290/ ACTAVIS GROUP PTC EHF. LV EMA/223740/2018 Page 14/18

15 Fludarabine/Actavis 25 mg/ml, πυκνό διάλυμα για παρασκευή ενέσιμου διαλύματος ή διαλύματος προς έγχυση Fludarabin Actavis 25 mg/ml injektio- /infuusiokonsentraatti, liuosta varten Fludarabinefosfaat Aurobindo 25 mg/ml, concentraat voor oplossing voor injectie of infusie Fludarabin Actavis 25 mg/ml koncentrat za raztopino za injiciranje/infundiranje FLUDARABINA AUROBINDO 25 mg/ml concentrato per soluzione iniettabile o per infusione FLUDARABINA AUROBINDO 25 mg/ml concentrato per soluzione iniettabile o per infusione UK/H/5290/ / ACTAVIS GROUP PTC EHF. GR UK/H/5290/ ACTAVIS GROUP PTC EHF. FI UK/H/5290/001 RVG AUROBINDO PHARMA B.V. NL UK/H/5290/001 H/13/00629/002 ACTAVIS GROUP PTC EHF. SI UK/H/5290/ AUROBINDO PHARMA (ITALIA) S.R.L. UK/H/5290/ AUROBINDO PHARMA (ITALIA) S.R.L. IT IT EMA/223740/2018 Page 15/18

16 Fludarabina Aurovitas 25 mg/ml concentrado para solución inyectable y para perfusión Fludarabin Aurobindo 25 mg/ml Konzentrat zur Herstellung einer Injektionslösung oder Infusionslösung Fludarabine Actavis, 25 mg/ml, koncentrat do sporzadzania roztworu do wstrzykiwan/do infuzji Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор Fludarabin Actavis 25mg/ml concentrate for solution for injection or infusion Fludarabine Actavis 25 mg/ml koncentratas injekciniam/infuziniam tirpalui UK/H/5290/ AUROVITAS SPAIN,S.A.U. ES UK/H/5290/ PUREN PHARMA GMBH & CO. KG UK/H/5290/ ACTAVIS GROUP PTC EHF. PL UK/H/5290/ ACTAVIS GROUP PTC EHF. BG UK/H/5290/001 IS/1/13/061/01 ACTAVIS GROUP PTC EHF. IS UK/H/5290/001 LT/1/13/3338/ ACTAVIS GROUP PTC EHF. LT DE EMA/223740/2018 Page 16/18

17 Fludarabine Actavis 25 mg/ml concentrat pentru solutie injectabila sau perfuzabila Fludarabine Phosphate 25mg/ml Concentrate for Solution for Injection or Infusion Fludarabinphosphat "Actavis", koncentrat til injektions- og infusionsvæske, opløsning Fludarabinphosphat Actavis 25 mg/ml Konzentrat zur Herstellung einer Injektions- oder Infusionslösung Fludarabin Actavis 25 mg/ml koncentrat za raztopino za injiciranje/infundiranje Fludarabine/Teva 25 mg/ml, πυκνό διάλυμα για παρασκευή ενέσιμου διαλύματος ή διαλύματος προς έγχυση UK/H/5290/ /2013/01-02 ACTAVIS GROUP PTC EHF. RO UK/H/5290/001 PL 30306/0442 ACTAVIS GROUP PTC EHF. UK UK/H/5290/ ACTAVIS GROUP PTC EHF. DK UK/H/5290/ ACTAVIS GROUP PTC EHF. AT UK/H/5290/001 H/13/00629/001 ACTAVIS GROUP PTC EHF. SI NL/H/0715/ /14 CHEMIPHARM S.G. DE TCHAVES & CIE E.E GR EMA/223740/2018 Page 17/18

18 FLUDARABINE EBEWE 25 mg/ml, solution à diluer injectable ou pour perfusion FLUDARABINE EBEWE 25 mg/ml, solution à diluer injectable ou pour perfusion FLUDARABINE EBEWE 25 mg/ml, solution à diluer injectable ou pour perfusion Fludarabine 25 mg/ml - concentrate for solution for injection or infusion Fludarabin HEXAL 25 mg/ml Konzentrat zur Herstellung einer Injektions- oder Infusionslösung not available SANDOZ FR not available SANDOZ FR not available SANDOZ FR DE/H/0801/001 PL 14510/ EBEWE PHARMA UK not available HEXAL AG DE EMA/223740/2018 Page 18/18

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

Package leaflet: Information for the user. Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine

Package leaflet: Information for the user. Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine Package leaflet: Information for the user Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine Read all of this leaflet carefully before you start using this medicine

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion PACKAGE LEAFLET: INFORMATION FOR THE USER ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using this medicine.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Package leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion

Package leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Package leaflet: Information for the user ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 February 2018 EMA/208334/2018 Human Medicines Evaluation Division Active substance: ibuprofen / pseudoephedrine Procedure no.: PSUSA/00001711/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN)

PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN) PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN) Read all of this leaflet carefully before you are given Oxaliplatin. - Keep this leaflet. You

More information

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user < Invented Name > 10 mg/ml concentrate for solution for infusion (50 mg/ 5 ml, 150 mg/15 ml, 450 mg/45 ml and 600 mg/60 ml) carboplatin Read all of this leaflet

More information

Package leaflet: Information for the patient. Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie

Package leaflet: Information for the patient. Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie Package leaflet: Information for the patient Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie Landiolol hydrochloride This medicine is subject to additional

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation Holder Austria

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

Version: 0005 February 2008 powder for solution for infusion Replaces: 0004 July 2007 PACKAGE LEAFLET: INFORMATION FOR THE USER

Version: 0005 February 2008 powder for solution for infusion Replaces: 0004 July 2007 PACKAGE LEAFLET: INFORMATION FOR THE USER Page: 1 Package Leaflet PACKAGE LEAFLET: INFORMATION FOR THE USER powder for solution for infusion Oxaliplatin Read all of this leaflet carefully before you start using this

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU

More information

BIJSLUITER: INFORMATIE VOOR DE PATIËNT

BIJSLUITER: INFORMATIE VOOR DE PATIËNT BIJSLUITER: INFORMATIE VOOR DE PATIËNT Sitagliptine Teva 25 mg, filmomhulde tabletten Sitagliptine Teva 50 mg, filmomhulde tabletten Sitagliptine Teva 100 mg, filmomhulde tabletten Sitagliptin Read all

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine.

More information

Package leaflet: Information for the user. Oxaliplatin 5 mg/ml, concentrate for solution for infusion. Oxaliplatin

Package leaflet: Information for the user. Oxaliplatin 5 mg/ml, concentrate for solution for infusion. Oxaliplatin Package leaflet: Information for the user Oxaliplatin 5 mg/ml, concentrate for solution for infusion Oxaliplatin Read all of this leaflet carefully before you start using this medicine because it contains

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metfmin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metfmin hydrochlide Read all of this leaflet carefully befe you start taking this medicine.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

BIJSLUITER: INFORMATIE VOOR DE PATIËNT

BIJSLUITER: INFORMATIE VOOR DE PATIËNT PACKAGE LEAFLET 1 BIJSLUITER: INFORMATIE VOOR DE PATIËNT Cinacalcet 30 mg Teva, filmomhulde tabletten Cinacalcet 60 mg Teva, filmomhulde tabletten Cinacalcet 90 mg Teva, filmomhulde tabletten Cinacalcet

More information

Package leaflet: Information for the user Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabine phosphate

Package leaflet: Information for the user Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabine phosphate Package leaflet: Information for the user Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabine phosphate The name of your medicine is Fludarabine phosphate 25 mg/ml

More information

Irinotecan hydrochloride 20 mg/ml Concentrate For Solution for Infusion Irinotecan hydrochloride trihydrate

Irinotecan hydrochloride 20 mg/ml Concentrate For Solution for Infusion Irinotecan hydrochloride trihydrate Irinotecan hydrochloride 20 mg/ml Concentrate For Solution for Infusion Irinotecan hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because it contains important

More information

(DK/H/1774/001/R/001 Response on add CMS comments FRAR) OXALIPLATIN 150 MG; 50 MG POWDER FOR SOLUTION FOR INFUSION

(DK/H/1774/001/R/001 Response on add CMS comments FRAR) OXALIPLATIN 150 MG; 50 MG POWDER FOR SOLUTION FOR INFUSION Sandoz Business use only Page 1 of 10 Package leaflet: Information for the patient Oxaliplatin Ebewe 5mg/ml powder for solution for infusion Oxaliplatin Read all of this leaflet carefully before you are

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide 20 mg/ml Concentrate for Solution for Infusion Etoposide

PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide 20 mg/ml Concentrate for Solution for Infusion Etoposide PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Keep this leaflet. You may

More information

Package Leaflet: Information For The User. Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion irinotecan hydrochloride trihydrate

Package Leaflet: Information For The User. Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion irinotecan hydrochloride trihydrate Package Leaflet: Information For The User Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion irinotecan hydrochloride trihydrate The name of your medicine is Irinotecan Hydrochloride

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Aurobindo 5 mg film-coated tablets Simvastatin Aurobindo 10 mg film-coated tablets Simvastatin Aurobindo 20 mg film-coated tablets Simvastatin Aurobindo

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

PATIENT INFORMATION LEAFLET. Midazolam 5 mg/ml Solution for Injection or Infusion midazolam

PATIENT INFORMATION LEAFLET. Midazolam 5 mg/ml Solution for Injection or Infusion midazolam PATIENT INFORMATION LEAFLET Midazolam 1 mg/ml Solution for Injection or Infusion Midazolam 5 mg/ml Solution for Injection or Infusion midazolam Read all of this leaflet carefully before you start taking

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine

More information

Package leaflet: Information for the user. Pemetrexed CF 25 mg/ml, concentraat voor oplossing voor infusie Pemetrexed

Package leaflet: Information for the user. Pemetrexed CF 25 mg/ml, concentraat voor oplossing voor infusie Pemetrexed Package leaflet: Information for the user Pemetrexed CF 25 mg/ml, concentraat voor oplossing voor infusie Pemetrexed Read all of this leaflet carefully before you start receiving this medicine because

More information

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic

More information

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Package leaflet: Information for the patient Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Tevaquel 25 mg Film-coated Tablets Tevaquel 100 mg Film-coated Tablets Tevaquel 150 mg Film-coated Tablets Tevaquel 200 mg Film-coated Tablets Tevaquel 300

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie

PACKAGE LEAFLET: INFORMATION FOR THE USER. Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie PACKAGE LEAFLET: INFORMATION FOR THE USER Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie Secretin pentahydrochloride Read all of this leaflet carefully

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user. Powder for concentrate for Solution for Infusion Ceftobiprolee

Package leaflet: Information for the user. Powder for concentrate for Solution for Infusion Ceftobiprolee PACKAGE LEAFLET 1 Zevtera 500 mg Powder for concentrate for Solution for Infusion Ceftobiprolee Read all of this leaflet carefully before you start using this medicine because it contains important informationn

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

Package leaflet: Information for the user. Paclitaxel 6 mg/ml, Concentrate for Solution for Infusion. Paclitaxel

Package leaflet: Information for the user. Paclitaxel 6 mg/ml, Concentrate for Solution for Infusion. Paclitaxel Package leaflet: Information for the user Paclitaxel 6 mg/ml, Concentrate for Solution for Infusion Paclitaxel Read all of this leaflet carefully before you start using this medicine because it contains

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER a Novartis Company PACKAGE LEAFLET: INFORMATION FOR THE USER Pantoprazole Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. -

More information

Package Leaflet: Information for the user. Caspofungin Clonmel 50 mg powder for concentrate for solution for infusion. Caspofungin

Package Leaflet: Information for the user. Caspofungin Clonmel 50 mg powder for concentrate for solution for infusion. Caspofungin Package Leaflet: Information for the user Caspofungin Clonmel 50 mg powder for concentrate for solution for infusion Caspofungin Read all of this leaflet carefully before you or your child are given this

More information

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Naloxone 400 micrograms/ml solution for injection/infusion. naloxone hydrochoride

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Naloxone 400 micrograms/ml solution for injection/infusion. naloxone hydrochoride PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Naloxone 400 micrograms/ml solution for injection/infusion naloxone hydrochoride Read all of this leaflet carefully before this medicine is administered to

More information

V020 1 B. PACKAGE LEAFLET

V020 1 B. PACKAGE LEAFLET V020 1 B. PACKAGE LEAFLET Package leaflet: Information for the patient Pantoprazole 40 mg powder for solution for injection pantoprazole sodium sesquihydrate Read all of this leaflet carefully before you

More information

Package leaflet: Information for the user. Clopidogrel 75 mg film-coated tablets. Clopidogrel

Package leaflet: Information for the user. Clopidogrel 75 mg film-coated tablets. Clopidogrel Package leaflet: Information for the user Clopidogrel 75 mg film-coated tablets Clopidogrel Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

Package leaflet: information for the user

Package leaflet: information for the user Package leaflet: information for the user Rosuvastatin 5 mg film-coated tablets Rosuvastatin 10 mg film-coated tablets Rosuvastatin 20 mg film-coated tablets Rosuvastatin 40 mg film-coated tablets rosuvastatin

More information

Package leaflet: Information for the user. Gemcitabine 40 mg/ml concentrate for solution for infusion. Gemcitabine

Package leaflet: Information for the user. Gemcitabine 40 mg/ml concentrate for solution for infusion. Gemcitabine Package leaflet: Information for the user Gemcitabine 40 mg/ml concentrate for solution for infusion Gemcitabine Read all of this leaflet carefully before you start using this medicine because it contains

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Valaciclovir Teva 500 mg Film-coated Tablets. Valaciclovir

PACKAGE LEAFLET: INFORMATION FOR THE USER. Valaciclovir Teva 500 mg Film-coated Tablets. Valaciclovir PACKAGE LEAFLET: INFORMATION FOR THE USER Valaciclovir Teva 500 mg Film-coated Tablets Valaciclovir Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may

More information

Package leaflet: Information for the user. Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil

Package leaflet: Information for the user. Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil Package leaflet: Information for the user Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil Read all of this leaflet carefully before you start taking this medicine

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Sevelamer Carbonate Rowex 800mg Film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains

More information

APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults

APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults Package Leaflet: Information for the User Read all of this leaflet carefully before you

More information

Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam

Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam Package leaflet : Information for the user Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam Read all of this leaflet carefully before you start

More information

Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin

Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin Read all of this leaflet

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user 50 mg, poeder voor concentraat voor oplossing voor infusie 70 mg, poeder voor concentraat voor oplossing voor infusie Caspofungin Read all of this leaflet carefully

More information

Package leaflet: Information for the patient. Leucovorine Sandoz 10 mg/ml, oplossing voor injectie folinic acid

Package leaflet: Information for the patient. Leucovorine Sandoz 10 mg/ml, oplossing voor injectie folinic acid Package leaflet: Information for the patient Leucovorine Sandoz 10 mg/ml, oplossing voor injectie folinic acid Read all of this leaflet carefully before you start using this medicine because it contains

More information